Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06139575 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 90 | Bivision Pharmaceuticals, Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04186585 | Recommended Dose Estimation of BP-C2 | recruiting | Phase 1 | 8 | MeddocOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02603965 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02339168 | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 | 25 | University of California, DavisOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06377683 | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 8 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite LavalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT06559007 | Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants | completed | Phase 1 | 24 | Atridia Pty Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06643494 | Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical | suspended | Phase 1 / Phase 2 | 100 | Optimal Health ResearchOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06866795 | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 1 | 42 | Geode Therapeutics Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT05332340 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | completed | Phase 1 | 12 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04428203 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 21 | Zin W MyintOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01792687 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | completed | Phase 1 | 6 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04421222 | Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer(EPI-7386) | terminated | Phase 1 | 71 | ESSA PharmaceuticalsINDUSTRY | 2 | Feb 28, 2025 | clinicaltrials |
| NCT05075577 | EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC | terminated | Phase 1 / Phase 2 | 77 | ESSA PharmaceuticalsINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT06783829 | A Study of SHR-4394 Injection in Subjects With Prostate Cancer | recruiting | Phase 1 | 240 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT03073395 | Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer | completed | Phase 1 | 30 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 43 | University of California, San FranciscoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 28 | Accutar Biotechnology IncINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06398470 | Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy | completed | Phase 1 / Phase 2 | 21 | University College, LondonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2025source: clinicaltrials